Zydus Lifesciences gets final nod for Sirolimus Tablets from USFDA

17 Feb 2023 Evaluate

Zydus Lifesciences (including its subsidiaries/affiliates hereafter referred to as ‘Zydus’) has received final approval from the United States Food and Drug Administration (USFDA) for Sirolimus Tablets, 1 mg and 2 mg (USRLD: Rapamune Tablets). Rapamune is used to prevent rejection (anti-rejection medicine) in people 13 years of age and older who have received a kidney transplant. It is also given to treat a rare lung disorder called lymphangioleiomyomatosis which predominantly affects women of childbearing age. The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya.

Sirolimus Tablets had annual sales of $69 million in the United States. The group now has 342 approvals and has so far filed over 440 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.

Zydus Lifesciences Share Price

911.50 -5.95 (-0.65%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×